These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22200089)

  • 1. Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
    Cranendonk DR; van der Valk M; Langenberg ML; van der Meer JT
    Scand J Infect Dis; 2012 May; 44(5):363-8. PubMed ID: 22200089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region.
    Laupland KB; Gregson DB; Church DL; Ross T; Pitout JD
    Clin Microbiol Infect; 2008 Nov; 14(11):1041-7. PubMed ID: 19040476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men.
    Livermore DM; Nichols T; Lamagni TL; Potz N; Reynolds R; Duckworth G
    J Antimicrob Chemother; 2003 Dec; 52(6):1040-2. PubMed ID: 14585850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England.
    Abernethy JK; Johnson AP; Guy R; Hinton N; Sheridan EA; Hope RJ
    Clin Microbiol Infect; 2015 Mar; 21(3):251.e1-8. PubMed ID: 25698659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.
    Lee SS; Kim Y; Chung DR
    J Infect; 2011 Feb; 62(2):159-64. PubMed ID: 21055417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model.
    Vellinga A; Tansey S; Hanahoe B; Bennett K; Murphy AW; Cormican M
    J Antimicrob Chemother; 2012 Oct; 67(10):2523-30. PubMed ID: 22729920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aspects of the antimicrobial resistence profile in infections with Escherichia coli and Klebsiella pneumoniae in diabetic patients].
    Petrovici CG; Dorobăţ C; Matei M; Teodor A; Luca V; Miftode E
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):769-75. PubMed ID: 22046785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates.
    Lin CY; Huang SH; Chen TC; Lu PL; Lin WR; Chen YH
    J Microbiol Immunol Infect; 2008 Aug; 41(4):325-31. PubMed ID: 18787740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia.
    Cheong HS; Kang CI; Kwon KT; Heo ST; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    J Antimicrob Chemother; 2007 Dec; 60(6):1355-60. PubMed ID: 17923453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting.
    Gottesman BS; Carmeli Y; Shitrit P; Chowers M
    Clin Infect Dis; 2009 Sep; 49(6):869-75. PubMed ID: 19686074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A matched prospective cohort study on Staphylococcus aureus and Escherichia coli bloodstream infections: extended perspectives beyond resistance.
    Berger J; Diab-Elschahawi M; Blacky A; Pernicka E; Spertini V; Assadian O; Koller W; Aichberger KJ
    Am J Infect Control; 2010 Dec; 38(10):839-45. PubMed ID: 20650546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.
    Andersen NF; Møller J; Peterslund NA
    Scand J Infect Dis; 2005; 37(2):90-5. PubMed ID: 15764199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.
    van der Bij AK; van Dijk K; Muilwijk J; Thijsen SF; Notermans DW; de Greeff S; van de Sande-Bruinsma N;
    Clin Microbiol Infect; 2012 Nov; 18(11):E466-72. PubMed ID: 22925456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Blot S; Vandijck D; Vandewoude K; Depuydt P; Vogelaers D; Peleman R
    J Antimicrob Chemother; 2007 Dec; 60(6):1402. PubMed ID: 17913718
    [No Abstract]   [Full Text] [Related]  

  • 18. Genome-wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of Escherichia coli.
    Yamane T; Enokida H; Hayami H; Kawahara M; Nakagawa M
    Int J Urol; 2012 Apr; 19(4):360-8. PubMed ID: 22211478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.
    Park SH; Choi SM; Lee DG; Kim J; Choi JH; Kim SH; Kwon JC; Yoo JH
    Microb Drug Resist; 2011 Dec; 17(4):537-44. PubMed ID: 21875342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.